Kessler, Galen
Kessler, Galen was paid $2.00M by Medicaid between Jan 2018 and Mar 2024, across 139 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 20% of everything it billed.
PEORIA, IL 61637
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,220 | $207K | |
| 2019 | 36,909 | $220K | |
| 2020 | 37,639 | $262K | |
| 2021 | 40,979 | $509K | |
| 2022 | 37,908 | $413K | |
| 2023 | 35,121 | $298K | |
| 2024incomplete | 12,861 | $92K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 20% | 6,926 | 5,685 | $392K |
| 80053 | Comprehensive metabolic panel | 5.8% | 22,648 | 19,034 | $117K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 5.5% | 446 | 431 | $109K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.5% | 3,937 | 3,751 | $90K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.5% | 3,936 | 3,750 | $90K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.4% | 29,735 | 23,254 | $87K |
| 88307 | 3.7% | 1,406 | 1,271 | $74K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 3.6% | 2,524 | 2,359 | $72K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.5% | 1,358 | 1,265 | $70K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.4% | 6,009 | 5,606 | $48K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.3% | 1,940 | 1,697 | $46K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.9% | 7,330 | 6,771 | $38K |
127 more codes
| 87480 | 1.8% | 2,811 | $35K | |
| 87510 | 1.8% | 2,807 | $35K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 889 | $33K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 7,557 | $32K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.6% | 453 | $31K |
| 88341 | 1.6% | 640 | $31K | |
| 88304 | 1.3% | 1,395 | $26K | |
| 82803 | 1.2% | 2,345 | $24K | |
| 83735 | 1.2% | 6,831 | $24K | |
| 87040 | 1.2% | 2,394 | $24K | |
| 87660 | 1.2% | 2,956 | $24K | |
| 88342 | 1.1% | 1,154 | $22K | |
| 83605 | 1.0% | 3,684 | $20K | |
| 82962 | <1% | 9,942 | $18K | |
| 87641 | <1% | 709 | $16K | |
| 87081 | <1% | 5,713 | $16K | |
| 84484 | <1% | 3,002 | $14K | |
| 82330 | <1% | 1,643 | $14K | |
| 80061 | Lipid panel | <1% | 3,950 | $13K |
| 87186 | <1% | 2,282 | $13K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 823 | $12K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,628 | $12K |
| 85730 | <1% | 2,529 | $11K | |
| 85610 | <1% | 4,970 | $10K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 764 | $10K |
| 86780 | <1% | 1,137 | $10K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 172 | $10K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,959 | $9K |
| 83690 | <1% | 2,640 | $9K | |
| 86850 | <1% | 2,815 | $8K | |
| 81001 | <1% | 5,303 | $8K | |
| 80069 | <1% | 1,787 | $7K | |
| 81025 | <1% | 3,681 | $7K | |
| 83880 | <1% | 720 | $7K | |
| 86901 | <1% | 3,023 | $7K | |
| 84439 | <1% | 1,587 | $7K | |
| 84100 | <1% | 3,041 | $7K | |
| 86140 | <1% | 2,661 | $6K | |
| 82607 | <1% | 952 | $6K | |
| 86900 | <1% | 2,980 | $5K | |
| 82728 | <1% | 1,267 | $5K | |
| 87088 | <1% | 891 | $5K | |
| 86803 | <1% | 584 | $5K | |
| 88141 | <1% | 414 | $5K | |
| 85384 | <1% | 1,455 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 178 | $4K |
| 84466 | <1% | 1,017 | $4K | |
| 87147 | <1% | 2,482 | $4K | |
| 87581 | <1% | 173 | $4K | |
| 80202 | <1% | 586 | $4K | |
| 82570 | <1% | 1,678 | $4K | |
| 87486 | <1% | 173 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 171 | $4K |
| 87070 | <1% | 1,139 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 467 | $4K |
| 85379 | <1% | 951 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 155 | $3K |
| 81003 | <1% | 3,083 | $3K | |
| 84702 | <1% | 700 | $3K | |
| 82784 | <1% | 399 | $3K | |
| 83540 | <1% | 914 | $3K | |
| 87340 | <1% | 409 | $3K | |
| 82550 | <1% | 889 | $3K | |
| 85027 | <1% | 994 | $3K | |
| 83615 | <1% | 959 | $3K | |
| 85014 | <1% | 2,077 | $2K | |
| 85652 | <1% | 1,448 | $2K | |
| 80047 | <1% | 394 | $2K | |
| 82746 | <1% | 301 | $2K | |
| 82805 | <1% | 65 | $2K | |
| 83970 | <1% | 107 | $2K | |
| 87205 | <1% | 767 | $1K | |
| 86003 | <1% | 39 | $1K | |
| 87077 | <1% | 457 | $1K | |
| 82565 | <1% | 588 | $1K | |
| 82043 | <1% | 663 | $1K | |
| 86038 | <1% | 161 | $1K | |
| 87493 | <1% | 51 | $1K | |
| 83516 | <1% | 192 | $1K | |
| 84550 | <1% | 538 | $1K | |
| 85018 | <1% | 1,073 | $1K | |
| 84703 | <1% | 299 | $1K | |
| 84478 | <1% | 398 | $891.54 | |
| 84132 | <1% | 489 | $861.27 | |
| 86920 | <1% | 194 | $836.27 | |
| 82247 | <1% | 332 | $831.04 | |
| 84156 | <1% | 714 | $796.55 | |
| 84295 | <1% | 452 | $787.11 | |
| 86480 | <1% | 29 | $714.19 | |
| 87505 | <1% | 14 | $713.75 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 75 | $656.27 |
| 87536 | <1% | 15 | $586.59 | |
| 82947 | <1% | 354 | $582.67 | |
| 86762 | <1% | 120 | $542.53 | |
| 83655 | <1% | 84 | $477.39 | |
| 82248 | <1% | 221 | $438.56 | |
| 84146 | <1% | 66 | $416.76 | |
| 80076 | <1% | 120 | $412.74 | |
| 85045 | <1% | 320 | $405.47 | |
| 82785 | <1% | 60 | $279.11 | |
| 87075 | <1% | 35 | $240.63 | |
| 84481 | <1% | 51 | $229.24 | |
| 87807 | <1% | 44 | $216.29 | |
| 86360 | <1% | 16 | $211.36 | |
| 82140 | <1% | 47 | $203.21 | |
| 86706 | <1% | 26 | $182.00 | |
| 80177 | <1% | 37 | $173.12 | |
| 85576 | <1% | 14 | $164.34 | |
| 82951 | <1% | 27 | $163.80 | |
| 86359 | <1% | 15 | $158.48 | |
| 82077 | <1% | 14 | $145.04 | |
| 85347 | <1% | 47 | $124.46 | |
| 80164 | <1% | 27 | $117.40 | |
| 82670 | <1% | 14 | $117.32 | |
| 82533 | <1% | 17 | $110.73 | |
| 86880 | <1% | 28 | $102.95 | |
| 88312 | <1% | 12 | $94.40 | |
| 87184 | <1% | 19 | $76.50 | |
| 86376 | <1% | 18 | $67.69 | |
| 86592 | <1% | 38 | $67.00 | |
| 86431 | <1% | 21 | $66.97 | |
| 85049 | <1% | 47 | $66.24 | |
| 87210 | <1% | 13 | $56.40 | |
| 82950 | <1% | 21 | $53.60 | |
| 81015 | <1% | 35 | $45.85 | |
| 84300 | <1% | 13 | $29.68 | |
| 86308 | <1% | 12 | $28.80 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.